Article Text

PDF
▼Paclitaxel and ▼docetaxel in breast and ovarian cancer
  • Relevant BNF section: 8.1.5

Abstract

Three years ago we reviewed paclitaxel (Taxol - Bristol-Myers Squibb), the first taxoid cytotoxic drug to be marketed.1 At that time it was licensed for the treatment of women with metastatic ovarian cancer resistant to standard platinum-containing therapy; we concluded that any benefits of paclitaxel were unproven. Since then the licence has been extended to include first-line treatment (in combination with cisplatin) of advanced ovarian cancer and treatment of metastatic carcinoma of the breast in patients who have failed, or are not candidates for, standard anthracycline-containing therapy. A second taxoid, docetaxel (Taxotere - Rhône-Poulenc Rorer) was launched in 1996. It is licensed for the treatment of patients with breast cancer that is locally advanced or metastatic, and which is either resistant to, or has recurred after, cytotoxic therapy, or has relapsed during adjuvant cytotoxic therapy. In each case, the previous cytotoxic therapy should have included an anthracycline drug (such as doxorubicin). Here we review the place of the two taxoids in the treatment of ovarian and breast cancer.

Statistics from Altmetric.com

  • Relevant BNF section: 8.1.5

View Full Text

Footnotes

    Request permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.